News and Announcements
Imugene (AXS: IMU) Commences Phase 1b/2 Gastric Cancer Study, Receives Approvals to Initiate Clinical Trial & Secures Further Intellectual Property
- Published August 11, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Imugene Limited (ASX: IMU), an immunoncology company is pleased to release its Appendix 4C for the quarter ended 30th June, 2017.
KEY TAKEAWAYS:
- Commenced the Phase 1b/2 gastric cancer study for HER-Vaxx
- Received full and final country regulatory approvals to initiate clinical trial;
- Commenced patient recruitment in all 8 clinical sites in Thailand, Taiwan and Hong Kong
- Secured further intellectual property for HER-Vaxx
- Completed further development of the next generation of mimotope targets and pipeline
- Commenced in vivo testing of arginine modulator in animal models of cancer
Imugene (ASX:IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.
Company Updates
Everything is now competing for the same dollar
Key takeaways As recently as 2022, Germany and Japan could borrow for 30 years at close to zero. That world is gone, and AI is now bidding for what is left. Over the past fortnight, I listened to founders, operators and allocators describe where their industries are heading. They covered four very different frontiers. Each […]
Australia has not held 90 days of fuel since 2012. The fix may start at a sewage plant.
A decommissioned council treatment site in Bundaberg is being built into a $188.9 million biorefinery. Its managing director is candid that the largest revenue line is not yet contracted. Australia has not met its international 90-day fuel reserve obligation since 2012. Around 90 per cent of the country’s liquid fuel is imported. Andy Whitmore, Managing […]
Forget Startups: Why Magnetic Alliance is Betting on “Boring” Mid-Market Turnarounds
While Australia’s venture capital scene spent years chasing unprofitable tech startups and speculative high-growth plays, Mark Lim was quietly taking a radically different path. The Managing Partner of Magnetic Alliance Capital sees the nation’s richest investment opportunities hiding in plain sight: inside thousands of unglamorous, profitable, but operationally sluggish mid-market businesses. Speaking on Wholesale Investor’s […]
Backed By Leading Investment Groups and Family Offices
